Charlotte Benson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3947534/publications.pdf

Version: 2024-02-01

		394421	414414
55	1,146	19	32
papers	citations	h-index	g-index
55	55	55	1814
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma Journal of Clinical Oncology, 2021, 39, 11518-11518.	1.6	2
2	Clinical management and outcomes of primary ovarian leiomyosarcoma – Experience from a sarcoma specialist unit. Gynecologic Oncology Reports, 2021, 36, 100737.	0.6	9
3	Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncology, 2021, 17, 2659-2670.	2.4	6
4	Embryonal and Alveolar Rhabdomyosarcoma in Adults: Real-Life Data From a Tertiary Sarcoma Centre. Clinical Oncology, 2020, 32, e27-e35.	1.4	12
5	Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Research, 2020, 40, 7003-7007.	1.1	3
6	Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. Clinical Sarcoma Research, 2020, 10, 9.	2.3	5
7	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 †CaboGIST†. European Journal of Cancer, 2020, 134, 62-74.	2.8	42
8	Robotic surgery for gastric gastrointestinal stromal tumors: A single center case series. Journal of Surgical Oncology, 2020, 122, 691-698.	1.7	7
9	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. British Journal of Cancer, 2020, 122, 1158-1165.	6.4	17
10	Pazopanib as a choice for advanced solitary fibrous tumour. Lancet Oncology, The, 2020, 21, 332-333.	10.7	2
11	Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202 Journal of Clinical Oncology, 2020, 38, 11556-11556.	1.6	O
12	Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance. Annals of Surgical Oncology, 2019, 26, 4699-4706.	1.5	36
13	The Role of Local Therapy in Multi-focal Epithelioid Haemangioendothelioma. Anticancer Research, 2019, 39, 4891-4896.	1.1	13
14	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. British Journal of Cancer, 2019, 120, 1026-1032.	6.4	33
15	Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Research, 2019, 39, 347-351.	1.1	O
16	Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST Journal of Clinical Oncology, 2019, 37, 11006-11006.	1.6	9
17	The Value of Anti-angiogenics in Soft Tissue Sarcoma Therapy. , 2019, , 465-473.		0
18	Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 147-151.	1.3	21

#	Article	IF	CITATIONS
19	Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Medical Oncology, 2018, 35, 138.	2.5	26
20	Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Medical Oncology, 2018, 35, 131.	2.5	14
21	Gemcitabine re-challenge in metastatic soft tissue sarcoma: A therapeutic option for selected patients Journal of Clinical Oncology, 2018, 36, 11559-11559.	1.6	0
22	Paediatric, adolescent, wild type, syndromic gastrointestinal stromal tumours (PAWS-GIST): Report from United Kingdom PAWS-GIST clinic Journal of Clinical Oncology, 2018, 36, e23519-e23519.	1.6	0
23	The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities. British Journal of Cancer, 2017, 116, 669-678.	6.4	48
24	Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anti-Cancer Drugs, 2017, 28, 421-426.	1.4	36
25	The Value of Anti-Angiogenics in Soft Tissue Sarcoma Therapy. , 2017, , 1-10.		0
26	Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study. Acta Oncol \tilde{A}^3 gica, 2017, 56, 1769-1775.	1.8	29
27	Uterine sarcoma & Description of Women's Health, 2017, Volume 9, 597-606.	2.6	86
28	Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series. BMC Cancer, 2017, 17, 717.	2.6	13
29	Influence of chemotherapy combined with radiotherapy on the time-to-development of radiation-induced sarcomas: A multicenter, retrospective analysis Journal of Clinical Oncology, 2017, 35, 11046-11046.	1.6	0
30	Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Gynecologic Oncology, 2016, 142, 89-94.	1.4	54
31	Desmoplastic Small Round Cell Tumor. International Journal of Surgical Pathology, 2016, 24, 672-684.	0.8	50
32	DOG1 Expression in Low-Grade Fibromyxoid Sarcoma. International Journal of Surgical Pathology, 2015, 23, 454-460.	0.8	18
33	First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma. Clinical Sarcoma Research, 2015, 5, 10.	2.3	13
34	Effective Downsizing of a Large Oesophageal Gastrointestinal Stromal Tumour with Neoadjuvant Imatinib Enabling an Uncomplicated and without Tumour Rupture Laparoscopic-Assisted Ivor-Lewis Oesophagectomy. Case Reports in Oncological Medicine, 2015, 2015, 1-6.	0.3	12
35	Current and advancing systemic treatment options for soft tissue sarcomas. Expert Opinion on Pharmacotherapy, 2015, 16, 2023-2037.	1.8	1
36	Metastatic soft tissue sarcoma, an analysis of systemic therapy and impact on survival Journal of Clinical Oncology, 2015, 33, 10545-10545.	1.6	13

3

#	Article	IF	CITATIONS
37	Serum troponin surveillance to predict cardiotoxicity of doxorubicin in adults with metastatic sarcoma Journal of Clinical Oncology, 2015, 33, e21516-e21516.	1.6	0
38	Clinical management of aggressive fibromatosis/desmoid tumour. Expert Opinion on Orphan Drugs, 2014, 2, 1027-1036.	0.8	0
39	New drugs in sarcomas. Expert Opinion on Pharmacotherapy, 2014, 15, 221-229.	1.8	7
40	Angiosarcoma of the face and scalp: Effective systemic treatment in the older patient. Journal of Geriatric Oncology, 2014, 5, 276-280.	1.0	22
41	Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies. Nature Reviews Clinical Oncology, 2014, 11, 187-202.	27.6	185
42	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. Clinical Sarcoma Research, 2014, 4, 7.	2.3	47
43	Role of expert centres in the management of sarcomas $\hat{a}\in$ A UK perspective. European Journal of Cancer, 2014, 50, 1951-1956.	2.8	21
44	Desmoplastic small round cell tumour: the radiological, pathological and clinical features. Insights Into Imaging, 2013, 4, 111-118.	3.4	28
45	Elicitation of health state utilities in soft tissue sarcoma. Quality of Life Research, 2013, 22, 1697-1706.	3.1	21
46	Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clinical Sarcoma Research, 2013, 3, 13.	2.3	32
47	Desmoplastic small round cell tumour: characteristics and prognostic factors of 41 patients and review of the literature. Clinical Sarcoma Research, 2013, 3, 14.	2.3	49
48	Treatment options for leiomyosarcoma. Expert Opinion on Orphan Drugs, 2013, 1, 413-422.	0.8	1
49	Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma. Sarcoma, 2013, 2013, 1-6.	1.3	54
50	Antiangiogenic approach in soft-tissue sarcomas. Expert Review of Anticancer Therapy, 2013, 13, 975-982.	2.4	7
51	Update on imatinib for gastrointestinal stromal tumors: duration of treatment. OncoTargets and Therapy, 2013, 6, 1011.	2.0	16
52	Fistulation as a complication of intra-abdominal soft-tissue sarcomas; a case series. Journal of Radiology Case Reports, 2013, 7, 15-21.	0.4	16
53	Six-year survival of a patient with pulmonary artery angiosarcoma. Asian Cardiovascular and Thoracic Annals, 2012, 20, 728-730.	0.5	8
54	A retrospective study from the Royal Marsden Hospital (RMH) of patients with malignant perivascular epithelioid cell tumors (PEComa) receiving treatment with sirolimus (SI) or temsirolimus (TSI) Journal of Clinical Oncology, 2012, 30, 10038-10038.	1.6	2

#	Article	IF	CITATIONS
55	Treatment outcomes of primary mediastinal and intrathoracic great vessels sarcoma: Royal Marsden Hospital experience Journal of Clinical Oncology, 2012, 30, 10060-10060.	1.6	О